The Pharma Data

MARCH 25, 2021

These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. lead researcher and Professor in Breast Cancer Excellence in the Perelman School of Medicine at the University of Pennsylvania.

HR 52

HR Clinical Trials Clinical Trials Trials 52

The Pharma Data

APRIL 7, 2021

“Women with triple-negative breast cancer have historically had very few effective treatment options and faced a poor prognosis,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and global principal investigator of the ASCENT study.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

MAY 13, 2021

Following this program will help you lose weight fast, prevent yo-yoing, stabilize hormonal balance, and get back on track to leading a healthy life – all while never being hungry or having to go to the gym! Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men.

Insulin 52

Insulin Production Hormones Medicine 52

Drug Discovery World

MAY 10, 2023

While the discovery phase – which includes target discovery, target validation, lead compound identification, and lead compound optimisation – averages several years and $200 million, the majority of the research, time, and financial spend takes place downstream in drug development.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52